Novartis first partner in RWE collaboration for dermatology

PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program.

TARGET-DERM will gather real world, de-identified patient-level data from electronic medical records as well as claims data, starting with atopic dermatitis and eventually adding other immune-mediated inflammatory skin conditions...